Ariadna Giró-Perafita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ariadna Giró-Perafita has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Teresa Puig
Consejo Superior de Investigaciones Científicas
5 shared publications Glòria Oliveras
New Terapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain
3 shared publicationsAdriana Blancafort
New Therapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain
2 shared publications- Alireza Khodadadi-Jamayran
Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA
2 shared publications Ariadna Sarrats
New Terapeutics Targets Laboratory (TargetsLab), Department of Medical Sciences, University of Girona, Girona, Spain
2 shared publications- Aristotelis Tsirigos
Department of Pathology, New York University Grossman School of Medicine, New York, USA
2 shared publications
Latest Publications
- Open Access
- 25 February 2025
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (3) , 197-207
Healthcare resource utilization and costs associated with inadequate initial antibiotic treatment of bacteraemia produced by carbapenem-resistant Gram-negative bacilli (CRGNB): a descriptive, observational study in Spanish hospitals
Introduction: Carbapenem-resistant gram-negative bacilli (CRGNB) are one of the main causes of nosocomial infections, posing a major public health challenge. Blood stream infections (BSI) require special attention because of the higher morbidity and mortality associated. Objective: To assess the impact of initial adequate or inadequate antibiotic treatment on the length of stay (LOS) and healthcare resource utilisation of patients with bloodstream infections (BSI) caused by a Carbapenem-resistant gram-negative bacilli (CRGNB) in the Spanish clinical practice. Methodology: A descriptive, observational, retrospective chart review study of patients diagnosed with CRGNB bacteriemia in 6 Spanish public hospitals. Results: The overall median LOS of the total population (n=64) was 26.5 days (Q1: 16 days; Q3: 40 days). The median LOS for the initially adequately treated group was 27 days (Q1: 17; Q3: 50), and 24 days (Q1: 15; Q3: 38) for the initially inadequately treated (t-test p= 0.5031). In the Hospital Ward group (n=44), initially adequately treated patients spent hospitalised a median of 6 days less than the initially inadequately treated patients (18 days [Q1: 12; Q3: 27] vs 24 days [Q1: 15; Q3: 38] respectively, p=0.0269). In the total population analysis, initially adequately treated patients had a lower use of resources (20,895.02 € [Q1: 11,543.67 €; Q3: 61,773.17 €]) compared to initially inadequately treated patients (24,444.02 € [Q1: 11,571.63 €; Q3: 40,790.64 €). Conclusion: Results suggest that inadequate empirical treatment for BSI caused by CRGNB in the hospital ward could be associated with an increase in the LOS and resource utilization of these patients.
- 25 February 2025
- Published by Sociedad Espanola de Quimioterapia in Revista Española de Quimioterapia
- Vol. 38 (3) , 197-207
Open AccessHealthcare resource utilization and costs associated with inadequate initial antibiotic treatment of bacteraemia produced by carbapenem-resistant Gram-negative bacilli (CRGNB): a descriptive, observational study in Spanish hospitals
Introduction: Carbapenem-resistant gram-negative bacilli (CRGNB) are one of the main causes of nosocomial infections, posing a major public health challenge. Blood stream infections (BSI) require special attention because of the higher morbidity and mortality associated. Objective: To assess the impact of initial adequate or inadequate antibiotic treatment on the length of stay (LOS) and healthcare resource utilisation of patients with bloodstream infections (BSI) caused by a Carbapenem-resistant gram-negative bacilli (CRGNB) in the Spanish clinical practice. Methodology: A descriptive, observational, retrospective chart review study of patients diagnosed with CRGNB bacteriemia in 6 Spanish public hospitals. Results: The overall median LOS of the total population (n=64) was 26.5 days (Q1: 16 days; Q3: 40 days). The median LOS for the initially adequately treated group was 27 days (Q1: 17; Q3: 50), and 24 days (Q1: 15; Q3: 38) for the initially inadequately treated (t-test p= 0.5031). In the Hospital Ward group (n=44), initially adequately treated patients spent hospitalised a median of 6 days less than the initially inadequately treated patients (18 days [Q1: 12; Q3: 27] vs 24 days [Q1: 15; Q3: 38] respectively, p=0.0269). In the total population analysis, initially adequately treated patients had a lower use of resources (20,895.02 € [Q1: 11,543.67 €; Q3: 61,773.17 €]) compared to initially inadequately treated patients (24,444.02 € [Q1: 11,571.63 €; Q3: 40,790.64 €). Conclusion: Results suggest that inadequate empirical treatment for BSI caused by CRGNB in the hospital ward could be associated with an increase in the LOS and resource utilization of these patients.
- Open Access
- 6 January 2020
- Published by Springer Nature in npj Breast Cancer
- Vol. 6 (1) , 1-14
LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer
Long non-coding RNAs (lncRNAs) play key roles in the regulation of breast cancer initiation and progression. LncRNAs are differentially expressed in breast cancer subtypes. Basal-like breast cancers are generally poorly differentiated tumors, are enriched in embryonic stem cell signatures, lack expression of estrogen receptor, progesterone receptor, and HER2 (triple-negative breast cancer), and show activation of proliferation-associated factors. We hypothesized that lncRNAs are key regulators of basal breast cancers. Using The Cancer Genome Atlas, we identified lncRNAs that are overexpressed in basal tumors compared to other breast cancer subtypes and expressed in at least 10% of patients. Remarkably, we identified lncRNAs whose expression correlated with patient prognosis. We then evaluated the function of a subset of lncRNA candidates in the oncogenic process in vitro. Here, we report the identification and characterization of the chromatin-associated lncRNA, RP11-19E11.1, which is upregulated in 40% of basal primary breast cancers. Gene set enrichment analysis in primary tumors and in cell lines uncovered a correlation between RP11-19E11.1 expression level and the E2F oncogenic pathway. We show that this lncRNA is chromatin-associated and an E2F1 target, and its expression is necessary for cancer cell proliferation and survival. Finally, we used lncRNA expression levels as a tool for drug discovery in vitro, identifying protein kinase C (PKC) as a potential therapeutic target for a subset of basal-like breast cancers. Our findings suggest that lncRNA overexpression is clinically relevant. Understanding deregulated lncRNA expression in basal-like breast cancer may lead to potential prognostic and therapeutic applications.
- 6 January 2020
- Published by Springer Nature in npj Breast Cancer
- Vol. 6 (1) , 1-14
Open AccessLncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer
Long non-coding RNAs (lncRNAs) play key roles in the regulation of breast cancer initiation and progression. LncRNAs are differentially expressed in breast cancer subtypes. Basal-like breast cancers are generally poorly differentiated tumors, are enriched in embryonic stem cell signatures, lack expression of estrogen receptor, progesterone receptor, and HER2 (triple-negative breast cancer), and show activation of proliferation-associated factors. We hypothesized that lncRNAs are key regulators of basal breast cancers. Using The Cancer Genome Atlas, we identified lncRNAs that are overexpressed in basal tumors compared to other breast cancer subtypes and expressed in at least 10% of patients. Remarkably, we identified lncRNAs whose expression correlated with patient prognosis. We then evaluated the function of a subset of lncRNA candidates in the oncogenic process in vitro. Here, we report the identification and characterization of the chromatin-associated lncRNA, RP11-19E11.1, which is upregulated in 40% of basal primary breast cancers. Gene set enrichment analysis in primary tumors and in cell lines uncovered a correlation between RP11-19E11.1 expression level and the E2F oncogenic pathway. We show that this lncRNA is chromatin-associated and an E2F1 target, and its expression is necessary for cancer cell proliferation and survival. Finally, we used lncRNA expression levels as a tool for drug discovery in vitro, identifying protein kinase C (PKC) as a potential therapeutic target for a subset of basal-like breast cancers. Our findings suggest that lncRNA overexpression is clinically relevant. Understanding deregulated lncRNA expression in basal-like breast cancer may lead to potential prognostic and therapeutic applications.
- Open Access
EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models
Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance. Furthermore, the enrichment of Breast Cancer Stem Cell (BCSC) features has been found in breast tumors that progressed after chemotherapy. Hence, we used the triple negative breast cancer (TNBC) cell line MDA-MB-231 (231) to evaluate the FASN and BCSC population role in resistance acquisition to chemotherapy. For this reason, parental cell line (231) and its derivatives resistant to doxorubicin (231DXR) and paclitaxel (231PTR) were used. The Mammosphere-Forming Assay and aldehyde dehydrogenase (ALDH) enzyme activity assay showed an increase in BCSCs in the doxorubicin-resistant model. Moreover, the expression of some transcription factors involved in epithelial-mesenchymal transition (EMT), a process that confers BCSC characteristics, was upregulated after chemotherapy treatment. FASN inhibitors C75, (−)-Epigallocatechin 3-gallate (EGCG), and its synthetic derivatives G28, G56 and G37 were used to evaluate the effect of FASN inhibition on the BCSC-enriched population in our cell lines. G28 showed a noticeable antiproliferative effect in adherent conditions and, interestingly, a high mammosphere-forming inhibition capacity in all cell models. Our preliminary results highlight the importance of studying FASN inhibitors for the treatment of TNBC patients, especially those who progress after chemotherapy.
Open AccessEGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models
Recent studies showed that Fatty Acid Synthase (FASN), a lipogenic enzyme overexpressed in several carcinomas, plays an important role in drug resistance. Furthermore, the enrichment of Breast Cancer Stem Cell (BCSC) features has been found in breast tumors that progressed after chemotherapy. Hence, we used the triple negative breast cancer (TNBC) cell line MDA-MB-231 (231) to evaluate the FASN and BCSC population role in resistance acquisition to chemotherapy. For this reason, parental cell line (231) and its derivatives resistant to doxorubicin (231DXR) and paclitaxel (231PTR) were used. The Mammosphere-Forming Assay and aldehyde dehydrogenase (ALDH) enzyme activity assay showed an increase in BCSCs in the doxorubicin-resistant model. Moreover, the expression of some transcription factors involved in epithelial-mesenchymal transition (EMT), a process that confers BCSC characteristics, was upregulated after chemotherapy treatment. FASN inhibitors C75, (−)-Epigallocatechin 3-gallate (EGCG), and its synthetic derivatives G28, G56 and G37 were used to evaluate the effect of FASN inhibition on the BCSC-enriched population in our cell lines. G28 showed a noticeable antiproliferative effect in adherent conditions and, interestingly, a high mammosphere-forming inhibition capacity in all cell models. Our preliminary results highlight the importance of studying FASN inhibitors for the treatment of TNBC patients, especially those who progress after chemotherapy.
- Open Access
- 5 February 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (16) , 12868-12878
Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process
Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process
- 5 February 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (16) , 12868-12878
Open AccessPrognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process
Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process
- Open Access
- 10 August 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (43) , 74391-74405
Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
Https://doi.org/10.18632/oncotarget.20152 Ariadna Giró-Perafita, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Maria Buxó, Joan Brunet, Gemma Viñas, Teresa Puig Miquel
- 10 August 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (43) , 74391-74405
Open AccessFatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
Https://doi.org/10.18632/oncotarget.20152 Ariadna Giró-Perafita, Ariadna Sarrats, Ferran Pérez-Bueno, Glòria Oliveras, Maria Buxó, Joan Brunet, Gemma Viñas, Teresa Puig Miquel
- Open Access
- 15 September 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (18) , 4687-4697
Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Purpose: Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse within 5 years after treatment. EGFR overexpression is a common marker in TNBC, and its expression has been correlated with poor outcome. Inhibition of fatty acid synthase (FASN) activity leads to apoptosis of human carcinoma cells overexpressing FASN. We tested the hypothesis that blocking FASN in combination with anti-EGFR signaling agents would be an effective antitumor strategy in sensitive and chemoresistant TNBC. Experimental Design: Several TNBC cell lines and 29 primary tumors were included to determine whether FASN is a potential target in TNBC. Doxorubicin-resistant TNBC cell lines (231DXR and HCCDXR) have been developed and characterized in our laboratory. Cellular and molecular interactions of anti-FASN compounds (EGCG and C75) with cetuximab were analyzed. In vivo tumor growth inhibition was evaluated after cetuximab, EGCG, or the combination in TNBC orthoxenograft models. Results: TNBC cell lines showed overexpression of FASN enzyme and its inhibition correlated to FASN levels. FASN staining was observed in all of the 29 TNBC tumor samples. In vitro, EGCG and C75 plus cetuximab showed strong synergism in sensitive and chemoresistant cells. In vivo, the combination of EGCG with cetuximab displayed strong antitumor activity against the sensitive and chemoresistant TNBC orthoxenografts, without signs of toxicity. Conclusions: Our results show that the simultaneous blockade of FASN and EGFR is effective in preclinical models of sensitive and chemoresistant TNBC. Clin Cancer Res; 22(18); 4687–97. ©2016 AACR.
- 15 September 2016
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 22 (18) , 4687-4697
Open AccessPreclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer
Purpose: Triple-negative breast cancer (TNBC) lacks an approved targeted therapy. Despite initial good response to chemotherapy, 30% of the patients relapse within 5 years after treatment. EGFR overexpression is a common marker in TNBC, and its expression has been correlated with poor outcome. Inhibition of fatty acid synthase (FASN) activity leads to apoptosis of human carcinoma cells overexpressing FASN. We tested the hypothesis that blocking FASN in combination with anti-EGFR signaling agents would be an effective antitumor strategy in sensitive and chemoresistant TNBC. Experimental Design: Several TNBC cell lines and 29 primary tumors were included to determine whether FASN is a potential target in TNBC. Doxorubicin-resistant TNBC cell lines (231DXR and HCCDXR) have been developed and characterized in our laboratory. Cellular and molecular interactions of anti-FASN compounds (EGCG and C75) with cetuximab were analyzed. In vivo tumor growth inhibition was evaluated after cetuximab, EGCG, or the combination in TNBC orthoxenograft models. Results: TNBC cell lines showed overexpression of FASN enzyme and its inhibition correlated to FASN levels. FASN staining was observed in all of the 29 TNBC tumor samples. In vitro, EGCG and C75 plus cetuximab showed strong synergism in sensitive and chemoresistant cells. In vivo, the combination of EGCG with cetuximab displayed strong antitumor activity against the sensitive and chemoresistant TNBC orthoxenografts, without signs of toxicity. Conclusions: Our results show that the simultaneous blockade of FASN and EGFR is effective in preclinical models of sensitive and chemoresistant TNBC. Clin Cancer Res; 22(18); 4687–97. ©2016 AACR.
- Open Access
- 1 January 2016
- Published by Elsevier in Procedia CIRP
- Vol. 49, 61-66
Optimization of Poli(ɛ-caprolactone) Scaffolds Suitable for 3D Cancer Cell Culture
- 1 January 2016
- Published by Elsevier in Procedia CIRP
- Vol. 49, 61-66
Open AccessOptimization of Poli(ɛ-caprolactone) Scaffolds Suitable for 3D Cancer Cell Culture
- Open Access
- 24 June 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0131241
Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical HER2+ breast cancer models of trastuzumab and lapatinib resistance. We developed and molecularly characterized in vitro HER2+ models of resistance to trastuzumab (SKTR), lapatinib (SKLR) and both (SKLTR). The cellular interactions of combining anti-FASN polyphenolic compounds (EGCG and the synthetic G28UCM) with anti-HER2 signaling drugs (trastuzumab plus pertuzumab and temsirolimus) were analyzed. Tumor growth inhibition after treatment with EGCG, pertuzumab, temsirolimus or the combination was evaluated in two in vivo orthoxenopatients: one derived from a HER2+ patient and another from a patient who relapsed on trastuzumab and lapatinib-based therapy. SKTR, SKLR and SKLTR showed hyperactivation of EGFR and p-ERK1/2 and PI3KCA mutations. Dual-resistant cells (SKLTR) also showed hyperactivation of HER4 and recovered levels of p-AKT compared with mono-resistant cells. mTOR, p-mTOR and FASN expression remained stable in SKTR, SKLR and SKLTR. In vitro, anti-FASN compounds plus pertuzumab showed synergistic interactions in lapatinib- and dual- resistant cells and improved the results of pertuzumab plus trastuzumab co-treatment. FASN inhibitors combined with temsirolimus displayed the strongest synergistic interactions in resistant cells. In vivo, both orthoxenopatients showed strong response to the antitumor activity of the combination of EGCG with pertuzumab or temsirolimus, without signs of toxicity. We showed that the simultaneous blockade of FASN and HER2 pathways is effective in cells and in breast cancer models refractory to anti-HER2 therapies.
- 24 June 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0131241
Open AccessDual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Blocking the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of HER2-positive breast carcinoma cells. The hypothesis is that blocking FASN, in combination with anti-HER2 signaling agents, would be an effective antitumor strategy in preclinical HER2+ breast cancer models of trastuzumab and lapatinib resistance. We developed and molecularly characterized in vitro HER2+ models of resistance to trastuzumab (SKTR), lapatinib (SKLR) and both (SKLTR). The cellular interactions of combining anti-FASN polyphenolic compounds (EGCG and the synthetic G28UCM) with anti-HER2 signaling drugs (trastuzumab plus pertuzumab and temsirolimus) were analyzed. Tumor growth inhibition after treatment with EGCG, pertuzumab, temsirolimus or the combination was evaluated in two in vivo orthoxenopatients: one derived from a HER2+ patient and another from a patient who relapsed on trastuzumab and lapatinib-based therapy. SKTR, SKLR and SKLTR showed hyperactivation of EGFR and p-ERK1/2 and PI3KCA mutations. Dual-resistant cells (SKLTR) also showed hyperactivation of HER4 and recovered levels of p-AKT compared with mono-resistant cells. mTOR, p-mTOR and FASN expression remained stable in SKTR, SKLR and SKLTR. In vitro, anti-FASN compounds plus pertuzumab showed synergistic interactions in lapatinib- and dual- resistant cells and improved the results of pertuzumab plus trastuzumab co-treatment. FASN inhibitors combined with temsirolimus displayed the strongest synergistic interactions in resistant cells. In vivo, both orthoxenopatients showed strong response to the antitumor activity of the combination of EGCG with pertuzumab or temsirolimus, without signs of toxicity. We showed that the simultaneous blockade of FASN and HER2 pathways is effective in cells and in breast cancer models refractory to anti-HER2 therapies.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_4) , iv60
Triple Negative Breast Cancer: Clinicopathologic Characteristics and Fatty Acid Synthase (Fasn) Expression As a Potential Target
Aim: Triple negative breast cancer (TNBC) is defined by the lack of estrogen and progesterone receptors expression and the absence of human epidermal growth factor receptor 2 amplification. TNBC has specific clinical/pathological features and molecular biology. The absence of effective targeted therapies requires new biomarkers to develop therapeutic strategies. FASN, the sole mammalian enzyme capable of de novo fatty acid synthesis, is highly expressed in several carcinomas. FASN is associated with poor prognosis and its inhibition is selectively cytotoxic to breast cancer cells. Therefore, lipogenesis mediated by FASN represents a potential target. The aim of our study was to evaluate the clinical and histopathologic features of a large population of TNBC patients and to analyze FASN expression in vitro and in vivo. Methods: We retrospectively evaluated 91 cases of primary TNBC diagnosed between 1990 and 2012 in our institution. We collected clinical/pathological features: age, histology, grade, stage, surgery and chemotherapy. FASN expression was preliminarily evaluated in 30 core-biopsy of TNBC patients by immunohistochemistry (IHC). FASN expression was graded from 0 to 3+ (0-1+ normal, 2+ moderate and 3+ high). Concurrently, we evaluated the cytotoxic effect of FASN inhibitors (cerulenin, C75 and EGCG), alone or in combination, in subtypes of TNBC cell lines (MDA-MB-231, BT549, MDA-MB-468, HCC1806). Results: Mean age was 54 years. Most of the tumors were grade 3 (85,2%) and ductal (85,9%). Mean ki 67 index was 64,5%. The type of surgery was 49,4% mastectomies and 43,5% lumpectomies (7,1% not operated). 22% of the patients had stage I, 43% II, 31,4% III and 3,6% stage IV. 90,6% patients received chemotherapy. The most common regimen was a combination of antraciclines and taxanes. The preliminary results showed that 20 patients had a high FASN expression (FASN 3+) and 10 had a moderate expression (FASN 2+). In vitro, FASN inhibitors displayed strong cytotoxicity in MDA-MB-468 and HCC1806 cells and moderate in MDA-MB-231 and BT549 cells. The combination of EGCG with cetuximab or doxorubicin in TNBC cells improved the results of the monotherapy. Conclusions: FASN is highly expressed in TNBC tumors. The absence of effective target therapies for this subtype and its poor prognosis, led to exploring the role of FASN as a potential target for TNBC therapy. Disclosure: All authors have declared no conflicts of interest.
- 1 September 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_4) , iv60
Triple Negative Breast Cancer: Clinicopathologic Characteristics and Fatty Acid Synthase (Fasn) Expression As a Potential Target
Aim: Triple negative breast cancer (TNBC) is defined by the lack of estrogen and progesterone receptors expression and the absence of human epidermal growth factor receptor 2 amplification. TNBC has specific clinical/pathological features and molecular biology. The absence of effective targeted therapies requires new biomarkers to develop therapeutic strategies. FASN, the sole mammalian enzyme capable of de novo fatty acid synthesis, is highly expressed in several carcinomas. FASN is associated with poor prognosis and its inhibition is selectively cytotoxic to breast cancer cells. Therefore, lipogenesis mediated by FASN represents a potential target. The aim of our study was to evaluate the clinical and histopathologic features of a large population of TNBC patients and to analyze FASN expression in vitro and in vivo. Methods: We retrospectively evaluated 91 cases of primary TNBC diagnosed between 1990 and 2012 in our institution. We collected clinical/pathological features: age, histology, grade, stage, surgery and chemotherapy. FASN expression was preliminarily evaluated in 30 core-biopsy of TNBC patients by immunohistochemistry (IHC). FASN expression was graded from 0 to 3+ (0-1+ normal, 2+ moderate and 3+ high). Concurrently, we evaluated the cytotoxic effect of FASN inhibitors (cerulenin, C75 and EGCG), alone or in combination, in subtypes of TNBC cell lines (MDA-MB-231, BT549, MDA-MB-468, HCC1806). Results: Mean age was 54 years. Most of the tumors were grade 3 (85,2%) and ductal (85,9%). Mean ki 67 index was 64,5%. The type of surgery was 49,4% mastectomies and 43,5% lumpectomies (7,1% not operated). 22% of the patients had stage I, 43% II, 31,4% III and 3,6% stage IV. 90,6% patients received chemotherapy. The most common regimen was a combination of antraciclines and taxanes. The preliminary results showed that 20 patients had a high FASN expression (FASN 3+) and 10 had a moderate expression (FASN 2+). In vitro, FASN inhibitors displayed strong cytotoxicity in MDA-MB-468 and HCC1806 cells and moderate in MDA-MB-231 and BT549 cells. The combination of EGCG with cetuximab or doxorubicin in TNBC cells improved the results of the monotherapy. Conclusions: FASN is highly expressed in TNBC tumors. The absence of effective target therapies for this subtype and its poor prognosis, led to exploring the role of FASN as a potential target for TNBC therapy. Disclosure: All authors have declared no conflicts of interest.